GlassScriptPhysician profile
Evan B Gold
NPI 1760441034
$4,456.87
in general payments reported to CMS, 2019-2025
14 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $151 · 2021: $611 · 2022: $1,313 · 2023: $758 · 2024: $524 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,211.62 | 2019-2025 | Argos, Clareon, Lensx |
| Beaver-Visitec International, INC. | $350.00 | 2022 | |
| Allergan, INC. | $231.10 | 2019-2022 | |
| Ocular Therapeutix, INC. | $170.07 | 2020-2025 | Dextenza |
| Abbvie INC. | $100.63 | 2023 | |
| Amgen INC. | $66.56 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $58.73 | 2019-2021 | |
| Horizon Therapeutics Plc | $47.36 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $45.28 | 2025 | |
| Biotissue Holdings INC. | $43.65 | 2024 | |
| Rayner Intraocular Lenses Limited | $40.65 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Sight Sciences, INC. | $40.54 | 2022-2023 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $29.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.